

Together Pharma receives IMC-GAP approval for its medical cannabis farm in Ashkelon, Israel

With the completion of cultivation of its first 180 plants, according to regulator demands by the Israeli Ministry of Health's Medical Cannabis Unit, the company has received IMC-GAP approval for its Israeli farm, which will allow the company to switch to commercial cultivation on a major scale

Ashkelon, October 16 2019 – [Together Pharma](#) (TASE: TGDR), an Israeli company specializing in cultivating and producing medical cannabis has reported that it has switched to commercial cultivation at its farm facility in Ashkelon, after receiving IMC-GAP approval for the facility. The facility in Ashkelon covers 5 acres and the company holds agreements to make products of IMC-GMP standard through a third party.

Consequently, with the completion of the first commercial crop within several months, the company will send its medical cannabis produce to its IMC-GMP standard factory, and will be able to supply products to pharmacies and medical cannabis patients in Israel, who in recent months have been suffering from a severe shortage of products. Some of the crops from the farm will be sent for producing oil products under the Cannabliss brand, which is part of the Together Pharma Group.

Together Pharma CEO Nissim Bracha: "We are switching to commercial operations in Israel too. Our farm in the Ashkelon region, which is operating under the new regulation, and has now received the required standard, is planned to produce significant amounts of medical cannabis produce and allows us to sell, after the first round of crops, medical cannabis products to pharmacies in Israel. We believe that the anticipated sale from the farm will position the company in the forefront of active cannabis companies."

The company is working towards starting to market products in Israel through pharmacies according to the new regulation and with the export approval expected in the coming months, Together will already be ready with products to market to Europe.

Together recently announced that it had completed the acquisition of Cannabliss, an Israeli company that has been operating for 10 years in the medical cannabis sector, in a deal worth about NIS 14 million. Cannabliss has a collaboration agreement with Hadassah Medical Center in Ein Kerem, Jerusalem, in which the company has an instruction and treatment unit that has provided broad medical cannabis solutions for thousands of patients since it was set up. Cannabliss' management and staff have major experience and knowhow in developing products, and managing a factory for the manufacture of medical cannabis products and treating patients,

and they will continue to manage the company. They will also be responsible for managing and operating the GMP standard factory that Together is setting up under the new regulation.

Together is also active in the CBD-based cosmetics field together with Premier Dead Sea. The companies have an agreement with a Dutch company, which has a factory in the Netherlands with all the required regulatory approvals for manufacturing cosmetics products containing CBD ingredients from the cannabis plant. The companies plan to manufacture thousands of units of three approved products, which will be distributed to sales points in countries where the products have been legalized.

About Together and Globus Pharma

Together (TASE: TGDR) is active in the field of medical cannabis through its subsidiary Globus Pharma, which is currently developing an advanced agricultural and technological infrastructure for the growing, production and marketing of medical cannabis products in Israel and abroad. The Company has marketing and distribution agreements with leading medical cannabis companies in Germany and Canada, with a total volume of approximately 80 tons of produce annually. Together Pharma has a team of experts in growing cannabis with more than 20 years of knowledge and experience in the practical growing of cannabis and the Company is in advanced stages of receiving marketing approval in Germany and the entire European market, including the filing of an application for obtaining European export permit of medical cannabis products and obtaining a license to distribute them throughout Europe.

<https://together-pharma.com>